PLoS Genetics · 2016 · 49 citations · 32 references
Life SciencesGeneticsOncologyApoptosisEpigeneticsMolecular OncologyApoptosis In CancerApoptosis RegulationCancer EpigeneticsChromatinEpigenetic Alterations In CancerEpigenetic Regulation In CancerApoptosis TargetingHistone MarksP53-mediated ApoptosisP53-mediated Cell DeathRunx2 SignalingRunx2 Transcriptional RegulationRunx2-mediated RegulationTumor Suppressor P53
The inactivation of p53 creates a major challenge for inducing apoptosis in cancer cells. An attractive strategy is to identify and subsequently target the survival signals in p53 defective cancer cells. Here we uncover a RUNX2-mediated survival signal in p53 defective cancer cells. The inhibition of this signal induces apoptosis in cancer cells but not non-transformed cells. Using the CRISPR technology, we demonstrate that p53 loss enhances the apoptosis caused by RUNX2 knockdown. Mechanistically, RUNX2 provides the survival signal partially through inducing MYC transcription. Cancer cells have high levels of activating histone marks on the MYC locus and concomitant high MYC expression. RUNX2 knockdown decreases the levels of these histone modifications and the recruitment of the Menin/MLL1 (mixed lineage leukemia 1) complex to the MYC locus. Two inhibitors of the Menin/MLL1 complex induce apoptosis in p53 defective cancer cells. Together, we identify a RUNX2-mediated epigenetic mechanism of the survival of p53 defective cancer cells and provide a proof-of-principle that the inhibition of this epigenetic axis is a promising strategy to kill p53 defective cancer cells.
32
Model-based Analysis of ChIP-Seq (MACS)
Yong Zhang, Tao Liu, Clifford A. Meyer et al. · Genome biology · 2008 · 19.9K citations · Full text
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong, F. Ann Ran, David Cox et al. · Science · 2013 · 15.7K citations
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence, Petar Stojanov, Paz Polak et al. · Nature · 2013 · 5.7K citations · Full text
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Lawrence A. Donehower, Michele Harvey, Betty L. Slagle et al. · Nature · 1992 · 4.7K citations
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves et al. · Science · 2004 · 4.7K citations
Medicine, Oncology, Pharmacology +15